Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137555

Published: 2020

Journal Articles

Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies

Nicholas J. Short, MD, Shouhao Zhou, Chenqi Fu, Donald Berry, MD PhD, Roland P Walter, MDPhD, Sylvie D Freeman, Christopher S. Hourigan, MDDPhil, Xuelin Huang, PhD, Graciela M. Nogueras González, MPH, Hyunsoo Hwang, Xinyue Qi, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-135939

Published: 2020

Journal Articles

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Donald Berry, PhD, Kristine Broglio, MS, Carol Ward, MSc, Federico Mattiello, PhD, Deniz Sahin, BSc, Tina G Nielsen, MD PhD, Anna McGlothlin, PhD, Corrine Elliott, MS, Thomas E. Witzig, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Maurizio Martelli, MD, Lale Kostakoglu, MD MPH, Grzegorz Nowakowski, MD

Blood (2019) 134 (Supplement_1): 4101.

https://doi.org/10.1182/blood-2019-124067

Published: 2019

Journal Articles

NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival

Daniela Buglio, MD, PhD, Manuela Lemoine, PhD, Sattva S. Neelapu, MD, Francisco Vega, MD, PhD, Donald Berry, Anas Younes, MD

Blood (2011) 118 (21): 4965.

https://doi.org/10.1182/blood.V118.21.4965.4965

Published: 2011

Journal Articles

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Luis Fayad, MD, Jorge E Romaguera, MD, Larry W Kwak, MD, PhD, Sattva S. Neelapu, MD, Fredrick Hagemeister, MD, Barbara Pro, MD, Silvana de Castro Faria, MD, Yuan Ji, PhD, Donald Berry, Daniela Buglio, MD, PhD, L. Jeffrey Medeiros, MD

Blood (2011) 118 (21): 3718.

https://doi.org/10.1182/blood.V118.21.3718.3718

Published: 2011

Journal Articles

The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,

Daniela Buglio, MD, PhD, Manuela Lemoine, PhD, Jaymie Estrella, PhD, Sattva S. Neelapu, MD, Richard Eric Davis, MD, Laurence Doyle, MD, Richard F Little, MD, MPH, Donald Berry, Anas Younes, MD

Blood (2011) 118 (21): 3729.

https://doi.org/10.1182/blood.V118.21.3729.3729

Published: 2011

Journal Articles

Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

Daniela Buglio, MD, PhD, Sangeetha Palakurti, PhD, Francisco Vega, PhD, Sattva S. Neelapu, Donald Berry, PhD, Yuan Ji, PhD, Kate Byth, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2852.

https://doi.org/10.1182/blood.V116.21.2852.2852

Published: 2010

NARROW

Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,

Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,

Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only